GTBP logo

GTBP
GT Biopharma Inc

2,490
Mkt Cap
$12.32M
Volume
979,974.00
52W High
$3.85
52W Low
$0.38
PE Ratio
-0.03
GTBP Fundamentals
Price
$0.369
Prev Close
$0.3903
Open
$0.3999
50D MA
$0.469
Beta
0.72
Avg. Volume
693,259.46
EPS (Annual)
-$6.25
P/B
1.72
Rev/Employee
$0.00
$2.57
Loading...
Loading...
News
all
press releases
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know
GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·25d ago
News Placeholder
More News
News Placeholder
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·29d ago
News Placeholder
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape PR Newswire VANCOUVER, BC, Jan. 16, 2026 Issued on behalf...
PR Newswire·3mo ago
News Placeholder
GT Biopharma Submits IND For GTB-5550 TriKE To Treat Solid Tumors
(RTTNews) - GT Biopharma, Inc. (GTBP) on Thursday said it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for GTB-5550 TriKE, designed to target...
Nasdaq News: Markets·3mo ago
News Placeholder
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.read more...
Benzinga·3mo ago
News Placeholder
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines PR Newswire...
PR Newswire·4mo ago
News Placeholder
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 PR Newswire VANCOUVER, BC, Dec. 19...
PR Newswire·4mo ago
News Placeholder
Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Platform Technologies Drive $211B Surge in Precision Cancer Treatment Platform Technologies Drive $211B Surge in Precision Cancer Treatment PR Newswire VANCOUVER, BC, Dec. 11, 2025 Issued on behalf...
PR Newswire·4mo ago
News Placeholder
Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment
This article is based on TheStreet's Stock & Markets Podcast. Hosted by Chris Versace, the veteran Wall Street investor and lead portfolio manager for TheStreet Pro, the weekly podcasts are available...
TheStreet.com·4mo ago
News Placeholder
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points PR Newswire VANCOUVER, BC, Dec...
PR Newswire·4mo ago
<
1
2
...
>

Latest GTBP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.